Two phase II first-line trials include a study of onartuzumab or placebo in combination with carboplatin/cisplatin and paclitaxel in untreated patients with squamous cell carcinoma (NCT01519804) and a study of onartuzumab or placebo plus bevacizumab/carboplatin/paclitaxel or cisplatin/pemetrexed in NSCLC patients (NCT01496742). in select adenocarcinoma populations,5,6improving upon clinical outcomes obtained with earlier clinical trials of platinum […]